A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Registrational
- Acronyms OCTAVE; OCTAVE long-term; OCTAVE Open; OLE
- Sponsors Pfizer
- 17 Oct 2023 Results assessing final safety analyses from the tofacitinib UC ((NCT00787202; NCT01465763; NCT01458951; NCT01458574,NCT01470612, NCT03281304) presented at the 31st United European Gastroenterology Week
- 01 Sep 2023 Results assessing health-related quality of life (HRQoL) outcomes in patients with ulcerative colitis published in the Inflammatory Bowel Diseases
- 31 Jul 2023 Results of post hoc pooled analysis from OCTAVE Sustain and OCTAVE Open, published in the Advances in Therapy